双龙抗纤胶囊对结缔组织病相关肺纤维化患者血清KL-6及T淋巴细胞亚群的影响
Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis
- 上海中医药杂志 2021年55卷第5期 页码：41-45
- 作者机构：
1.河北医科大学附属石家庄平安医院风湿病科（河北 石家庄 050021）
2.河北医科大学附属石家庄平安医院实验诊断学部（河北 石家庄 050021）
- 作者简介：
钮含春，女，硕士，副主任医师，主要从事中西医结合治疗风湿免疫病的临床研究工作
王晓军，主任医师，硕士研究生导师；E-mail：wangxiaojun0826@163.com
- 基金信息：河北省中医药管理局科研计划项目(2019423)
DOI：10.16305/j.1007-1334.2021.2005149
中图分类号：
扫 描 看 全 文
钮含春, 李晓云, 白明明, 等. 双龙抗纤胶囊对结缔组织病相关肺纤维化患者血清KL-6及T淋巴细胞亚群的影响[J]. 上海中医药杂志, 2021,55(5):41-45.
Hanchun NIU, Xiaoyun LI, Mingming BAI, et al. Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(5):41-45.
钮含春, 李晓云, 白明明, 等. 双龙抗纤胶囊对结缔组织病相关肺纤维化患者血清KL-6及T淋巴细胞亚群的影响[J]. 上海中医药杂志, 2021,55(5):41-45. DOI： 10.16305/j.1007-1334.2021.2005149.
Hanchun NIU, Xiaoyun LI, Mingming BAI, et al. Effect of Shuanglong Antifibrin Capsule on KL-6 and T lymphocyte subsets in patients with connective tissue disease associated with pulmonary fibrosis[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(5):41-45. DOI： 10.16305/j.1007-1334.2021.2005149.
摘要
目的,2,观察双龙抗纤胶囊对结缔组织病相关肺纤维化患者血清涎液化糖链抗原（KL-6）及外周血T淋巴细胞亚群的影响。,方法,2,将80例结缔组织病相关肺纤维化患者随机分为治疗组和对照组，每组40例。两组均给予基础治疗，治疗组加用双龙抗纤胶囊，对照组加用安慰剂。两组疗程均为12周，观察中医证候积分、肺部高分辨CT评分，以及血清KL-6和外周血T淋巴细胞亚群（CD4,+,、CD8,+,、CD4,+,/CD8,+,）水平的变化情况。,结果,2,①治疗过程中，治疗组、对照组各脱落2例，完成试验者两组各38例。②治疗前后组内比较，两组中医证候积分、血清KL-6水平均降低(,P,<,0.05)，肺部高分辨CT评分无明显变化(,P,>,0.05)；组间治疗后比较，治疗组中医证候积分、血清KL-6水平均低于对照组(,P,<,0.05)，肺部高分辨CT评分比较差异无统计学意义(,P,>,0.05)。③治疗前后组内比较，治疗组CD4,+,T淋巴细胞、CD4,+,/CD8,+,均升高(,P,<,0.05)，CD8,+, T淋巴细胞明显下降(,P,<,0.05)，对照组CD4,+,T淋巴细胞、CD8,+, T淋巴细胞、CD4,+,/CD8,+,均无明显变化(,P,>,0.05)；组间治疗后比较，治疗组CD4,+,、CD8,+,、CD4,+,/CD8,+,水平均优于对照组(,P,<,0.05)。,结论,2,双龙抗纤胶囊治疗结缔组织病相关肺纤维化有一定疗效，其机制可能与降低肺泡Ⅱ型上皮细胞分泌KL-6，提高外周血CD4,+,T淋巴细胞、降低CD8,+,T淋巴细胞水平，改善细胞免疫有关。
Abstract
Objective,2,To observe the efficacy of Shuanglong Antifiber Capsule (SAC) in patients with connective tissue disease associated with pulmonary fibrosis and its effect on serum KL-6 and T lymphocyte subsets in peripheral blood.,Methods,2,A total of 80 patients with pulmonary fibrosis in connective tissue disease were randomly divided into treatment group and control group, 40 cases in each group. On the basic treatment, the treatment group was treated with SAC, and the control group was treated with placebo. The treatment course was 12 weeks. The TCM syndrome score, high resolution CT(HRCT) score, peripheral blood T lymphocyte subsets (CD4,+, CD8,+,) levels and serum levels of KL-6 were compared between the two groups.,Results,2,①During the treatment, 2 cases were lost and 38 cases were completed the experiment in each group.②After treatment, the TCM syndrome scores and serum KL-6 level of both groups were decreased (,P,<,0.05), but the HRCT scores of both groups were no significant changes (,P,>,0.05). The TCM syndrome scores and serum KL-6 level in the treatment group were lower than those in the control group (,P,<,0.05).But the HRCT scores were no statistical difference between the two groups (,P,>,0.05). ③After treatment, CD4,+,T lymphocytes and CD4,+,/CD8,+, in the treatment group were increased (,P,<,0.05), and CD8,+, T lymphocytes were decreased (,P,<,0.05), while there were no significant changes in CD4,+,T lymphocytes, CD8,+, T lymphocytes and CD4,+,/CD8,+, in the control group (,P,>,0.05).After treatment, CD4,+,T lymphocytes, CD8,+,T lymphocytes and CD4,+,/CD8,+, in the treatment group were better than those in the control group (,P,<,0.05).,Conclusions,2,SAC had good efficacy in the treatment of connective tissue disease associated with pulmonary fibrosis. The mechanism might be associated with the decreased expression of KL-6 which secreted by alveolar epithelial cells Ⅱ. In addition, SAC could improve CD4,+,T lymphocytes and decrease CD8,+,T lymphocytes of the peripheral blood to adjust cellular immunity.
关键词
双龙抗纤胶囊结缔组织病肺纤维化KL-6T淋巴细胞亚群临床观察
Keywords
Shuanglong Antifibrin Capsuleconnective tissue diseasepulmonary fibrosisKL-6T lymphocyte subsetsclinical observation
references
SHIBOSKI C H, SHIBOSKI S C, SEROR R, et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheum, 2017, 69(1): 35-45.
ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569-2581.
VAN DEN HOOGEN F, KHANNA D, FRANSEN J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative[J]. Arthritis Rheum, 2013, 65(11): 2737-2747.
RAGHU G, REMY-JARDIN M, MYERS J L, et al. Diagnosis of idiopathic pulmonary fibrosis：an official ATS/ERS/JRS/ALAT clinical practice guideline[J]. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
国家药品监督管理局. 中药新药临床研究指导原则（试行）[M]. 北京：中国医药科技出版社，2002: 53-56, 116-117.
安世英，赵文清，郑敏宇，等. 加味下瘀血汤联合乙酰半胱氨酸治疗间质性肺纤维化的临床研究[J]. 上海中医药杂志，2017, 51(9): 57-59.
李锐，叶冰玉，刘佳钰，等. 活血通络汤辨治类风湿关节炎合并肺间质纤维化临床研究[J]. 陕西中医， 2019, 40(8): 1041-1043.
刘洋，于盼，韩金花，等. 阳和益肺汤联合西药治疗肺肾阳虚型肺纤维化40例[J]. 上海中医药杂志，2019, 53(11): 53-56.
田丽，张伟. 从“络以通为用”论治肺间质纤维化[J]. 中医杂志，2018, 59(19): 1644-1646.
OHSHIMO S, YOKOYAMA A, HATTORI N, et al. KL-6，a human MUC1 mucin, promotes proliferation and survival of lung fibrosis[J]. Biochem Bioophys Res Commun, 2005, 338(4): 1845-1852.
XU L, YAN D R, ZHU S L, et al. KL-6 regulated the expression of HGF, collagen and myofibrob last differentiation[J]. Eur Rev Med Pharmacol Sci, 2013, 17(22): 3073-3077.
田新玮，刘丽丹，碧荣游，等. 消纤汤联合穴位贴敷治疗结缔组织病合并肺间质纤维化临床研究[J]. 四川中医，2019, 37(5): 90-93.
王慧莲，李松伟，王济华，等. 益气养阴通痹方治疗类风湿关节炎合并肺间质病变临床观察[J]. 中国实验方剂学杂志，2017, 23(7): 185-190.
曹雪涛，何维. 医学免疫学[M]. 北京：人民卫生出版社，2015: 202-207.
PAPIRIS S A, VLACHOYIANNOPOULOS P G, MANIATI M A, et al. Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: two fibroses with different prognoses[J]. Respiration, 1997, 64(1): 81-85.
PAPIRIS S A, KOLLINTZA A, KARATZA M, et al. CD8+T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis[J]. J Inflamm, 2007(4): 14.
黄庆，李志武，马志国，等. 地龙的研究进展[J]. 中国实验方剂学杂志， 2018, 24(13): 220-226.
江燕. 黄芪药理作用及在方剂配伍方面的应用[J]. 中国实用医药，2015, 10(1): 226-227.
王逸勤，郝一鸣. 从调节免疫力谈中医药防治新型冠状病毒肺炎[J]. 上海中医药杂志，2020, 54(5): 1-5.
杨建鑫，李向阳. 冬虫夏草活性成分虫草多糖的研究进展[J]. 中药材，2019, 42(4): 87-91.
0
浏览量
123
下载量
0
CSCD
0
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 沪ICP备13044091号
沪公网安备 31011502015228号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：70551 今日访问量：32